Zachary Schneiderman began his scientific career at the NIH, where he established the first non- affinity-based purification process for an HIV Trimer vaccine and co-lead a high-throughput development team. He then pursued his PhD in the Kokkoli laboratory where he works at the forefront of both DNA and lipid nanotechnology, focusing on targeted drug and gene therapy delivery for the treatment of cancer using DNA nanotubes, liposomes, and lipid nanoparticles. This work has led to thirteen co-authored publications and two patents and earned him the nanotechnology for cancer research fellowship. Since Zachary's first year in the lab, he has been the lab captain, safety captain, and recently led the "my green lab" certification process. Throughout his career, he has shown a dedication to mentoring students including several REU and graduate students, as well as many middle school students through his work with the Breakthrough Collaborative, a non-profit dedicated to educational equity.
Ph.D. , BioengineeringClass of 2023